Search Within

Even Holth Rustad

  1. "Sean Devlin"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Biostatistics Service (6)
  2. Center for Hematologic Malignancies (6)
  3. Department of Medicine (6)
  4. Department of Pathology and Laboratory Medicine (6)
  5. Epidemiology and Biostatistics (6)
  6. Hematologic Malignancies Research (6)

More Groups

People
  1. Caleb Ho (6)
  2. Malin Hultcrantz (6)
  3. Maria Arcila (6)
  4. Mikhail Roshal (6)
  5. Sean Devlin (6)
  6. Carl Landgren (5)

More People

Years
  1. 2021 (1)
  2. 2020 (1)
  3. 2019 (3)
  4. 2018 (1)
Publications
  1. Blood (4)
  2. PLoS ONE (1)
  3. The Lancet Haematology (1)
Publishers
  1. American Society of Hematology (4)
  2. Elsevier Science, Inc. (1)
  3. Public Library of Science (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
    Journal Article

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Chen, D.; Devlin, S. M.; more...
    PLoS ONE (2019)

    Fulltext@MSK | Save
  • V(D)J sequence capture for DNA-based minimal residual disease detection in multiple myeloma
    Meeting Abstract

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Devlin, S. M.; Jacobsen, A.; more...
    Blood (2018)

    Fulltext@MSK | Save